- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00034086
Study of Anti-HIV Therapy Intensification
Immunologic Consequences of Antiretroviral Therapy Intensification in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315/375
The purpose of this study is to see how the body's immune system changes after replacing and adding new anti-HIV drugs to a patient's current anti-HIV therapy. This study will also see whether adding drugs is safe. Patients who take part in A5136 are also eligible to take part in 2 substudies. The purpose of substudy A5140s is to see how many latently infected cells (cells in which the HIV virus survives) are in the lymph node (small, rounded structures that make disease-fighting cells). Substudy A5155s will be performed to see how many latently infected cells are in the blood before and after replacing and adding anti-HIV drugs.
ACTG A5136 is a follow-up study to ACTG 315 and ACTG 375, which were designed to examine the effects of highly active antiretroviral therapy (HAART) in certain HIV-infected patients. Many HIV-infected patients have undergone long-term anti-HIV therapy and have had the virus suppressed. However, most of these patients still have problems with their immune systems. The reason for these problems is unknown. This study may help researchers understand what causes immune system problems in people who have low levels of HIV in their blood.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Biologique: Vaccin antipneumococcique, polyvalent (23-valent)
- Médicament: Lamivudine
- Médicament: Stavudine
- Médicament: Zidovudine
- Médicament: Didanosine
- Médicament: Lamivudine/Zidovudine
- Médicament: Fumarate de ténofovir disoproxil
- Médicament: Lopinavir/Ritonavir
- Biologique: Lyme Disease Vaccine Recombinant OspA
- Biologique: Haemophilus B Conjugate Vaccine
Description détaillée
ACTG 315 and its follow-up study, ACTG 375, were designed to examine the immunologic and virologic consequences of highly active antiretroviral therapy (HAART) in patients with moderately advanced HIV-1 disease. At the conclusion of ACTG 375, patients eligible for participation in ACTG A5136 will have received over 5 years of antiretroviral therapy. Despite long-term therapy and long-term maximal viral suppression in most patients, significant immune defects such as impaired response to antigens, including HIV, abnormally low CD4 cell counts, abnormally high immune activation, and decreased expression of CD28 persist. It is uncertain whether these defects persist as a result of irreversible damage inflicted by HIV infection or ongoing immune perturbation resulting from continuous low-level HIV replication. Cellular reservoirs of HIV that persist (despite undetectable plasma viral load) may contribute to persistent immune activation and impaired immune function. A great deal of information on the relationship between low-level viral replication and persistent immune impairment may be gained by investigating these patients before and after intensification of their antiretroviral therapy regimens.
Patients continue to receive their ACTG 375 antiretroviral therapy until they register to A5136. Following entry evaluations, patients replace the protease inhibitors (PIs) in their ACTG 375 regimen with lopinavir/ritonavir (LPV/r), add tenofovir disoproxil fumarate (TDF) to their regimen, and maintain the rest of their ACTG 375 regimen for 48 weeks. Patients have clinic visits at entry and at Weeks 4, 12, and 16. After 24 weeks, patients have clinic visits every 12 weeks. Blood is drawn at these visits for viral load, immune response, and other routine tests. A skin test, a urine sample collection, and a pregnancy test (for women of reproductive potential) are also performed at entry. Patients also receive immunizations. At Weeks 12 and 16, a lyme vaccine, polyvalent is administered. At Week 36, lyme vaccine, polyvalent; pneumococcal vaccine, polyvalent; and haemophilus b conjugate (HIB) vaccine are administered [AS PER AMENDMENT 05/14/02: Lyme disease vaccine has been removed from the study due to unavailability]. At Week 48, skin tests are performed. Week 52 is the final clinic visit, at which blood is drawn and a urine sample is taken.
Patients who participate in substudy A5140s undergo 2 lymph node aspirates, at entry and at Week 48. Patients participating in substudy A5155s have blood drawn at screening and Week 48.
Type d'étude
Inscription
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Colorado
-
Aurora, Colorado, États-Unis
- University of Colorado Hospital CRS
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Rush Univ. Med. Ctr. ACTG CRS
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106
- Case CRS
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
Patients may be eligible for this study if they:
- Have completed ACTG 375 within 2 weeks of finishing Week 230.
- Have a viral load less than 400 copies/ml within 90 days prior to study entry.
- Agree not to become pregnant or to impregnate during the study. The female patient/male partner must use acceptable methods of contraception while receiving study drugs and for 1 month after stopping the drugs. Women and men who cannot have children are eligible without requiring the use of contraception, but they must provide acceptable documentation of menopause, sterilization, or lack of sperm cells.
Exclusion Criteria
Patients may not be eligible for this study if they:
- Need to use certain drugs within 30 days of study entry.
- Have taken any immunomodulatory therapies within 30 days prior to study entry unless approved by the protocol chairs.
- Have a history of serious kidney problems.
- Are allergic or sensitive to the study drugs.
- Are pregnant or breast-feeding.
- Have an alcohol or drug dependency that, in the opinion of the investigator, would interfere with the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Masquage: Aucun (étiquette ouverte)
Collaborateurs et enquêteurs
Les enquêteurs
- Chaise d'étude: Kimberly Smith
Dates d'enregistrement des études
Dates principales de l'étude
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections transmissibles par le sang
- Maladies transmissibles
- Maladies sexuellement transmissibles, virales
- Maladies sexuellement transmissibles
- Infections à lentivirus
- Infections à rétroviridae
- Syndromes d'immunodéficience
- Maladies du système immunitaire
- Infections à VIH
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-infectieux
- Agents antiviraux
- Inhibiteurs de la transcriptase inverse
- Inhibiteurs de la synthèse des acides nucléiques
- Inhibiteurs d'enzymes
- Agents anti-VIH
- Agents antirétroviraux
- Antimétabolites
- Facteurs immunologiques
- Inhibiteurs de protéase
- Inhibiteurs du cytochrome P-450 CYP3A
- Inhibiteurs des enzymes du cytochrome P-450
- Inhibiteurs de la protéase du VIH
- Inhibiteurs de la protéase virale
- Ténofovir
- Vaccins
- Vaccin conjugué contre le pneumocoque heptavalent
- Ritonavir
- Lopinavir
- Lamivudine
- Zidovudine
- Stavudine
- Didanosine
- Association de médicaments lamivudine et zidovudine
Autres numéros d'identification d'étude
- A5136
- 10680 (Identificateur de registre: DAIDS ES)
- ACTG A5136
- AACTG A5136
- ACTG A5140s- Substudy
- AACTG A5140s
- ACTG A5155s- Substudy
- AACTG A5155s
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Infections à VIH
-
Icahn School of Medicine at Mount SinaiIRRASRecrutementHémorragie intraventriculaire (HIV)États-Unis
-
Yale UniversityComplétéPrématurité | Nourrissons de très faible poids à la naissance | Hémorragie intraventriculaire (HIV) | Saignement dans le cerveauÉtats-Unis
-
West Virginia UniversityInscription sur invitationInfection de la peau et des tissus mous | Infection gastro-intestinale | Infection pulmonaire | Infection des os et des articulations | Infection endovasculaire | Infection génito-urinaireÉtats-Unis
-
Croydon Health Services NHS TrustComplétéInfection du site opératoire | Infection de la plaie | Césarienne; Infection | Infection périnéaleRoyaume-Uni
-
Taipei Medical University WanFang HospitalInconnue
-
Ondine Biomedical Inc.ComplétéInfection du site opératoire | Infection nosocomiale | Infection associée aux soins de santéÉtats-Unis
-
Angela BiancoStryker NordicRésiliéCésarienne | Infection du site opératoire | Infection nosocomialeÉtats-Unis
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Erasmus... et autres collaborateursRecrutementInfection prothétique-articulaire | Infection de la hanche | Infection; Genou, ArticulationPays-Bas
-
Cairo UniversityRecrutementInfection postopératoire | Complications de la césarienne | Infection vaginaleEgypte
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemComplétéInfection du site opératoire | Infection superficielle du site opératoire | Infection profonde du site chirurgical | Infection du site chirurgical d'un organe/de l'espaceÉtats-Unis
Essais cliniques sur Vaccin antipneumococcique, polyvalent (23-valent)
-
Seema BhatRecrutementLa leucémie lymphocytaire chronique | Petit lymphome lymphocytaireÉtats-Unis
-
University of UtahNational Cancer Institute (NCI)RecrutementLa leucémie lymphocytaire chronique | Petit lymphome lymphocytaireÉtats-Unis
-
Merck Sharp & Dohme LLCComplétéInfection pneumococcique
-
Sinovac Biotech Co., LtdComplétéInfections pneumococciquesChine
-
Sinovac Biotech Co., LtdComplétéInfections pneumococciquesChine
-
Ab&b Biotechnology Co., Ltd.JSHenan Center for Disease Control and PreventionComplété
-
Merck Sharp & Dohme LLCComplétéZona | Infection pneumococcique
-
National Institute of Allergy and Infectious Diseases...Lederle-Praxis BiologicalsComplétéInfections à VIH | Infections pneumococciquesÉtats-Unis, Porto Rico
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdActif, ne recrute pasVolontaires en bonne santéChine
-
National Cancer Institute (NCI)Actif, ne recrute pasLa leucémie lymphocytaire chronique | Petit lymphome lymphocytaire | Leucémie lymphoïde chronique de stade 0 | Leucémie lymphoïde chronique de stade I | Leucémie lymphoïde chronique de stade II | Ann Arbor Stade I Petit Lymphome Lymphocytaire | Lymphome lymphocytaire de stade II d'Ann Arbor | Leucémie... et d'autres conditionsÉtats-Unis